UK markets closed
  • FTSE 100

    6,915.75
    -26.47 (-0.38%)
     
  • FTSE 250

    22,251.26
    +3.72 (+0.02%)
     
  • AIM

    1,236.50
    -2.54 (-0.21%)
     
  • GBP/EUR

    1.1517
    -0.0005 (-0.05%)
     
  • GBP/USD

    1.3706
    -0.0029 (-0.21%)
     
  • BTC-GBP

    43,691.04
    +807.88 (+1.88%)
     
  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • DOW

    33,800.60
    +297.03 (+0.89%)
     
  • CRUDE OIL

    59.34
    -0.26 (-0.44%)
     
  • GOLD FUTURES

    1,744.10
    -14.10 (-0.80%)
     
  • NIKKEI 225

    29,768.06
    +59.08 (+0.20%)
     
  • HANG SENG

    28,698.80
    -309.27 (-1.07%)
     
  • DAX

    15,234.16
    +31.48 (+0.21%)
     
  • CAC 40

    6,169.41
    +3.69 (+0.06%)
     

Global Dermatology Drugs Global Market Report (2021 to 2030) - COVID-19 Impact and Recovery

Research and Markets
·9-min read

Dublin, April 02, 2021 (GLOBE NEWSWIRE) -- The "Dermatology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global dermatology drugs market as it emerges from the COVID-19 shut down.

The global dermatology drugs market is expected to grow from $37.57 billion in 2020 to $40.49 billion in 2021 at a compound annual growth rate (CAGR) of 7.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $62.83 billion in 2025 at a CAGR of 12%.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.

  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

  • Create regional and country strategies on the basis of local data and analysis.

  • Identify growth segments for investment.

  • Outperform competitors using forecast data and the drivers and trends shaping the market.

  • Understand customers based on the latest market research findings.

  • Benchmark performance against key competitors.

  • Utilize the relationships between key data sets for superior strategizing.

  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Where is the largest and fastest growing market for the dermatology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Dermatology Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider dermatology drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.

  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.

  • Market segmentations break down market into sub markets.

  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.

  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

  • The dermatology drugs market section of the report gives context. It compares the dermatology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, dermatology drugs indicators comparison.

Major companies in the dermatology drugs market include Johnson & Johnson; Allergan Plc; Galderma S.A; Novartis AG and GlaxoSmithKline Plc.

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne, microbial infections and other skin disorders. The dermatology market is segmented into acne; dermatitis; psoriasis; and other drugs for dermatology diseases.

Asia Pacific was the largest region in the global dermatology drugs market, accounting for 36% of the market in 2020. North America was the second largest region accounting for 27% of the global dermatology drugs market. Africa was the smallest region in the global dermatology drugs market.

Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs.

High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers.

The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China's GDP grew from $11 trillion in 2015 to $13.6 trillion in 2018. Additionally, according to the World Economic Outlook Reports by the IMF, emerging markets and developing economies together registered a growth of 4.0% in 2015 and this increased to 4.5% in 2018. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Dermatology Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Dermatology Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Dermatology Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Dermatology Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Dermatology Drugs Market Trends and Strategies

8. Impact of COVID-19 on Dermatology Drugs

9. Dermatology Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market

10. Dermatology Drugs Market Regional Analysis
10.1. Global Dermatology Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Dermatology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Dermatology Drugs Market, Growth and Market Share Comparison, by Region

11. Dermatology Drugs Market Segmentation
11.1. Global Dermatology Drugs Market, Segmentation by Type
11.2. Global Dermatology Drugs Market, Segmentation by Distribution Channel
11.3. Global Dermatology Drugs Market, Segmentation by Route of Administration
11.4. Global Dermatology Drugs Market, Segmentation by Drug Classification
11.5. Global Dermatology Drugs Market, Segmentation by Mode of Purchase

12. Dermatology Drugs Market Metrics
12.1. Dermatology Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Dermatology Drugs Market Expenditure, 2015-2025, Global

13. Asia-Pacific Dermatology Drugs Market

14. Western Europe Dermatology Drugs Market

15. Eastern Europe Dermatology Drugs Market

16. North America Dermatology Drugs Market

17. South America Dermatology Drugs Market

18. Middle East Dermatology Drugs Market

19. Africa Dermatology Drugs Market

20. Dermatology Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. Johnson & Johnson
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. Allergan Plc
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. Galderma S.A
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Novartis AG
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. GlaxoSmithKline Plc
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance

21. Key Mergers and Acquisitions in the Dermatology Drugs Market

22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)

23. Recommendations
23.1. Global Dermatology Drugs Market in 2025 - Growth Countries
23.2. Global Dermatology Drugs Market in 2025 - Growth Segments
23.3. Global Dermatology Drugs Market in 2025 - Growth Strategies

24. Appendix
24.1. NAICS Definitions of Industry Covered in This Report
24.2. Abbreviations
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher

25. Copyright and Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/uxvxn8

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900